Chronic stable angina is a clinical syndrome characterized by squeezing, heaviness or pressure discomfort in the chest, neck, jaw, shoulder, back, or arms which is usually precipitated by exertion and/or emotional stress and relieved by rest and/or Nitroglycerin.
It is caused by myocardial ischemia that is commonly associated with narrowing of the coronary arteries.
Angina is stable when it is not a new symptom and when there is no deterioration in frequency, duration or severity of episodes.
Percutaneous coronary intervention (PCI) with a thin composite wire strut, durable polymer-coated stent demonstrated comparable results to that using an ultrathin cobalt-chromium strut, bioresorbable polymer-coated stent, according to results of the BIONYX* trial presented at the recent TCT symposium (TCT 2018).
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
New drug applications approved by US FDA as of 1 - 15 September 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Lipoprotein apheresis, normally used for lipid control in heterozygous familial hypercholesterolaemia, has shown benefit in patients with refractory angina pectoris and raised lipoprotein(a) [Lp(a)] levels in a small phase III study presented at the European Society of Cardiology (ESC) Congress 2016 held recently in Rome, Italy. [Atheroscler Suppl 2015;18:103-108]
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.